Highest-materiality recent filing
OraSure stockholders approve board declassification and 5M share increase in stock plan
Stockholders approved 5M share increase to Stock Award Plan; total authorized shares now 6,982,477.
OraSure reports Q1 2026 results; specific financial figures not disclosed in filing excerpts
Issued press release with Q1 2026 consolidated financial results.
John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.
Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
Director David J. Shulkin resigns from OraSure board effective March 2, 2026
David J. Shulkin, M.D. resigned as director and from Compensation Committee, effective March 2, 2026.
OraSure announces Q4/FY2025 results; exhibit details not provided here
Press release and investor presentation furnished on Feb 25, 2026 for Q4 and full year ended Dec 31, 2025.
OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device
Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.
OraSure CEO and CFO adopt 10b5-1 plans to purchase up to $165K each in common stock
CEO Carrie Eglinton Manner adopted a plan to buy up to $165,000 of OSUR shares over six months.
OraSure Technologies Q3 2025 results announced; financial details not provided in filing exhibits
Company reported Q3 2025 consolidated financial results on November 5, 2025.
OraSure board chair Aspinall resigns; Boyd appointed director, Kenny named chair
Mara G. Aspinall resigned from the board and as chair effective Oct 28, 2025; no dispute cited.
Company issued press release for Q2 2025 consolidated financial results on August 5, 2025.
OraSure shareholders approve amendment to 2000 Stock Award Plan, increasing authorized shares by 6M
Stockholders approved amendment to Stock Award Plan to increase shares authorized for grant by 6,000,000 shares.
Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition
Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.
OraSure Chief Product Officer Kathleen Weber resigns, effective June 30, 2025
Kathleen G. Weber notified resignation as Chief Product Officer on May 8, 2025.
OraSure announces Q1 2025 financial results; specific figures not available in filing attachment
Press release dated May 7, 2025 reports Q1 2025 consolidated financial results.
OraSure announces $40M stock repurchase program, terminates 2008 plan
Board authorized up to $40M in common stock repurchases over two years on March 21, 2025.
Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition
Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26
Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.
Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing
OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.
OraSure Technologies reports Q3 2024 results; details not in filing excerpt
Press release and conference call held November 6, 2024 for Q3 2024 results.
OraSure expands board to 7 members, appoints John P. Kenny as independent director
Board increased from 6 to 7 directors; John P. Kenny appointed as Class I director, effective Sept 6.
OraSure reports Q2 2024 earnings; no figures in filing body
Press release issued August 6, 2024, covering Q2 2024 results and business developments.
Stockholders approved amendment to 2000 Stock Award Plan to increase authorized shares by 3,000,000; total now up to 5,302,283 shares.
OraSure announces Q1 2024 results; specific figures not disclosed in filing excerpt
Press release issued May 8, 2024 covering Q1 2024 financial results.
OraSure reports cybersecurity incident with data exfiltration; Q1 revenue guidance reaffirmed
Unauthorized third party gained access to certain information systems on or about March 27, 2024.
OraSure reports Q4/FY2023 results; press release not provided for review
Filed 8-K on Feb 27, 2024 announcing consolidated financial results for Q4 and FY2023.
On May 8, 2025, Kathleen G. Weber notified OraSure Technologies, Inc. (the “Company”) of her resignation as Chief Product Officer of the Company, effective June 30, 2025.
the Board appointed John P. Kenny as a new member of the Board, with such appointment to be effective as of the Effective Date.
Max materiality 0.70 · Median 0.50 · Most common event earnings